BioSyent Inc. (“BioSyent”)(TSX VENTURE: RX) announced today that its wholly owned subsidiary BioSyent Pharma Inc. (“BioSyent Pharma”) has signed a product sourcing and distribution agreement for the exclusive Canadian marketing and distribution rights of a compound that treats blood disorders. The agreement includes the acquisition of two Health Canada approved products and one with pending Health Canada approval.
